Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

FOLTA Adam JURCEK Tomas KUBESOVA Blanka ŽÁČKOVÁ Daniela SEMERÁD Lukáš MAYER Jiří JEŽÍŠKOVÁ Ivana

Year of publication 2021
Type Article in Periodical
Magazine / Source LEUKEMIA & LYMPHOMA
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1861274
Doi http://dx.doi.org/10.1080/10428194.2020.1861274
Keywords CE-IVD tests; BCR-ABL1 transcript monitoring; chronic myeloid leukemia
Description According to European Leukemia Network (ELN) recommendations, real-time quantitative PCR (qRT-PCR) is a conventional strategy for long-term BCR-ABL1 transcript monitoring in patients with chronic myeloid leukemia (CML) both during tyrosine kinase inhibitor (TKI) therapy and its discontinuation [1–5]. However, with the new Regulation (EU) 2017/746 coming, health institutions will have to start using CE-marked IVD (CE-IVD) devices (including kits, reagents, calibrators, etc.) for analyses. Thus, commercial CE-IVD tests will also enter into routine CML diagnostics in the near future.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.